Skip to main content

Advertisement

SpringerLink
Log in

The intestinal microbiome influences checkpoint blockade

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Studies in metastatic melanoma, non-small-cell lung carcinoma and renal cell carcinoma indicate certain bacteria within the gut microbiota enhance clinical responses to checkpoint blockade.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Colon microbiota may contribute to checkpoint-blockade response or nonresponse in patients with melanoma or epithelial cancers.

Marina Corral Spence/Springer Nature

References

  1. Topalian, S.L., Drake, C.G. & Pardoll, D.M. Cancer Cell 27, 450–461 (2015).

    Article  CAS  Google Scholar 

  2. Routy, B. et al. Science 359, 91–97 (2018).

    Article  CAS  Google Scholar 

  3. Gopalakrishnan, V. et al. Science 359, 97–103 (2018).

    Article  CAS  Google Scholar 

  4. Matson, V. et al. Science 359, 104–108 (2018).

    Article  CAS  Google Scholar 

  5. Chaput, N. et al. Ann. Oncol. 28, 1368–1379 (2017).

    Article  CAS  Google Scholar 

  6. Lynch, S.V. & Pedersen, O. N. Engl. J. Med. 375, 2369–2379 (2016).

    Article  CAS  Google Scholar 

  7. Viaud, S. et al. Science 342, 971–976 (2013).

    Article  CAS  Google Scholar 

  8. Iida N, et al. Science 342, 967–970 (2013).

    Article  CAS  Google Scholar 

  9. Vétizou, M. et al. Science 350, 1079–1084 (2015).

    Article  Google Scholar 

  10. Sivan, A. et al. Science 350, 1084–1089 (2015).

    Article  CAS  Google Scholar 

  11. Weber, J.S. et al. J. Clin. Oncol. 35, 785–792 (2017).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bloomberg-Kimmel Institute for Immunotherapy, Johns Hopkins University School of Medicine, Balitmore, Maryland, USA

    Cynthia L Sears & Drew M Pardoll

Authors
  1. Cynthia L Sears
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Drew M Pardoll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cynthia L Sears.

Ethics declarations

Competing interests

D.M.P. receives funding from Bristol–Myers Squibb and the Melanoma Research Alliance for immunotherapy research and consults for a number of companies with interests in immunotherapy, namely Compugen, GlaxoSmithKline, Medimmune/AstraZeneca, Merck, Potenza Therapeutics, Sanofi, Tizona, DNatrix, Amgen, Rock Springs Capital, Immunomic Therapeutics, Janssen, WindMil Therapeutics and Bayer. D.M.P. and C.L.S. are both supported by the Bloomberg-Kimmel Institute for Immunotherapy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sears, C., Pardoll, D. The intestinal microbiome influences checkpoint blockade. Nat Med 24, 254–255 (2018). https://doi.org/10.1038/nm.4511

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.4511

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation